IN THE CLAIMS:

Claims 9, 22, and 24-29 have been amended herein. All of the pending claims are presented below. This listing of claims will replace all prior versions and listings of claims in the application. Please enter these claims as amended.

Listing of the Claims:

1. (Previously presented) An aqueous micellar formulation for topical application to animals for the control of internal parasites, the formulation comprising a first active agent in combination with a second active agent, and:

from about 100 g to about 400 g veterinary-acceptable surfactant(s) per liter of the formulation;

from about 200 g to about 750 g veterinary-acceptable water-miscible to solvent(s) per liter of the formulation; and

from about 50 g to about 350 g of water per liter of the formulation;

wherein said first active agent is selected from the group consisting of water insoluble benzimidazoles, salicylanilides, active derivatives thereof, and salts of any thereof; and

wherein said second active agent is selected from the group consisting of macrocyclic lactones, active derivatives thereof, and of any salts thereof.

2. (Previously presented) A formulation according to claim 1, wherein said surfactant is selected from polyoxyethylene sorbitan- or sorbitol-fatty acid esters or combinations thereof.

3. (Original) A formulation according to claim 2, wherein said surfactant is polyoxyethylene (20) sorbitan monolaurate.

4. (Previously presented) A formulation according to claim 1, wherein said water miscible solvent is selected from the group consisting of ethanol, isopropanol, benzyl alcohol, glycol ethers, liquid polyoxyethylene glycols, and a mixture of at least two of these solvents.

5. (Previously presented) A formulation according to claim 4, wherein one or more of the glycol ethers are selected from the group consisting of alkylene and dialkylene glycol monoalkyl ethers.

6. (Previously presented) A formulation according to claim 5, wherein said one or more of glycol ethers are selected from the group consisting of propylene glycol monomethyl ether, diethylene glycol monoethyl ether, and diethylene glycol monobutyl ether.

7. (Previously presented) A formulation according to claim 4, comprising a glycol ether and a liquid polyoxyethylene glycol as water- miscible solvents.

8. (Previously presented) A formulation according to claim 7, wherein the polyoxyethylene glycol is PEG 200.

9. (Currently amended) A formulation according to claim 1, further comprising from about 5 g to about 50 g per ~~litre~~ liter of the formulation of a stabilizer selected from linear anionic surfactants, buffering agents and mixtures thereof.

10. (Previously presented) A formulation according to claim 9, wherein said stabilizer is selected from the group consisting of linear alkyl sulphates, linear alkyl benzene sulphonates, and phosphates, and mixtures thereof.

11. (Original) A formulation according to claim 10, wherein said stabilizer is sodium dodecyl sulphate.

12. (Previously presented) A formulation according to claim 1, comprising from about 100 g to about 300 g surfactant per liter of the formulation.

13. (Previously presented) A formulation according to claim 1, comprising from about 300 g to about 650 g water-miscible solvent(s) per liter of the formulation.

14. (Previously presented) A formulation according to claim 1, wherein said formulation comprises from about 10 g to about 100 g per liter of the formulation of a liquid polyoxyethylene glycol as a water-miscible solvent.

15. (Previously presented) A formulation according to claim 13, comprising about 450 g to about 550 g glycol ether(s) selected from alkylene or dialkylene glycol monoalkyl ethers, and about 20 g to about 50 g of a liquid polyoxyethylene glycol as the one or more water-miscible solvents per liter of the formulation.

16. (Previously presented) A formulation according to claim 1, comprising about 150 g water per liter of the formulation.

17. (Previously presented) A formulation according to claim 1, comprising from about 120 g to about 300 g benzimidazole, or a derivative thereof, per liter of the formulation.

18. (Previously presented) A formulation according to claim 16, wherein said first active agent is triclabendazole.

19. (Previously presented) A formulation according to claim 1, comprising from about 7.5 g to about 20 g macrocyclic lactone per liter of the formulation.

20. (Previously presented) A formulation according to claim 19, comprising about 15 g macrocyclic lactone per liter.

21. (Previously presented) A formulation according to claim 19, wherein said macrocyclic lactone is ivermectin.

22. (Currently amended) A formulation according to claim 1, comprising, per liter of the formulation:

from about 180 g to about 240 g benzimidazole;

from about 7.5 g to about 20 g macrocyclic lactone or an active derivative or salt thereof;

from about 150 g to about 250 g polyoxyethylene (20) sorbitan monolaurate;

from about 450 g to about 550 g diethylene glycol monobutyl ether;

from about 20 g to about 50 g PEG 200;

from about 10 g to about 30 g sodium dodecyl sulphate; and

from about 100 g to about 200 g of water.

23. (Previously presented) The formulation of claim 22 that comprises about 240 g triclabendazole and about 15 g ivermectin per liter.

24. (Withdrawn and Currently amended) A method of treating or preventing a diseased or parasite-infested state in ~~a mammal~~ an animal, the method comprising topically administering to ~~said mammal~~ the animal the aqueous micellar formulation according to claim 1, wherein said disease or parasite-infested state comprises a liver fluke infection or infestation, a nematode infection or infestation, or both a liver fluke and a nematode infection or infestation in the ~~mammal~~ animal.

25. (Withdrawn and Currently amended) A method according to claim 24, wherein ~~said mammal~~ the animal is selected from the group consisting of a head of cattle, a sheep, a goat, a pig and a horse.

26. (Withdrawn and Currently amended) A method according to claim 24, wherein said topical application comprises application of the formulation in a band along the lower portion of the ~~mammal's~~ animal's back.

27. (Withdrawn and Currently amended) A method according to claim 26, wherein the formulation is applied to the ~~mammal~~ animal over as small a region as possible, while avoiding run-off of the formulation so as to maximize the concentration of active agents per square centimeter of ~~mammal~~ animal surface.

28. (Withdrawn and Currently amended) A method according to claim 26, wherein the band of formulation is applied starting from the thoracic vertebrae and proceeding towards the rump of ~~to the mammal~~ the animal, ~~and from kilogram animal~~, about 18 mg to about 24 mg triclabendazole and from about 0.75 mg to about 2 mg ivermectin are applied per kilogram ~~mammal~~ animal.

29. (Withdrawn and Currently amended) The method of claim 28, wherein about 24 mg triclabendazole and about 15 mg ivermectin are applied per kilogram ~~mammal~~ animal.